肝素诱导性血小板减少症相关研究进展  

Research advances in heparin-induced thrombocytopenia

作　　者：张培蕾[1] 周耕[1] 程永德[2] 

机构地区：[1]上海交通大学附属第六人民医院放射介入科,200233 [2]解放军第85医院放射科

出　　处：《介入放射学杂志》2017年第5期385-389,共5页Journal of Interventional Radiology

摘　　要：肝素诱导性血小板减少症(HIT)是一种少见的危急性、免疫性普通肝素或低分子肝素引起的并发症。HIT在接受肝素治疗患者中的发病率为0.6%~5%,尤其是对心血管手术或介入治疗患者危害很大,是目前临床研究热点。本文就HIT发病机制、流行病学、临床评估和治疗等方面研究进展作一简要综述。Clinically, heparin-induced thrombocytopenia （HIT） is an uncommon but serious disease, which is induced by the use of immune unfraetionated heparin or low-molecular-weight heparin. The overall incidence of HIT is about 0.6%-5.0%. Nevertheless, in clinical practice it is profoundly dangerous, especially for patients who are receiving cardiovascular surgery or interventional therapy. At present, HIT is a hot clinical research subject. This paper aims to make a brief review about HIT pathogenesis, epidemiology, clinical evaluation and treatment, etc.（J Intervent Radiol, 2017, 26： 385-389）

关 键 词：肝素诱导性血小板减少症 流行病学 临床评估 治疗 腔内介入 

分 类 号：R558.2[医药卫生—血液循环系统疾病]